INTERLEUKIN 33 AND FIBROSIS: PATHOGENESIS UPDATED

Interleukin 33 (IL-33) is a member of the IL-1 family, which is widely expressed on all types of cells. IL-33 was identified as a functional ligand for the plasma membrane receptor complex, which is a heterodimer consisting of a membrane bound ST2 receptor (growth stimulating factor). IL-33 is invol...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	E. G. Uchasova, O. V. Gruzdeva, Yu. A. Dileva, V. N. Karetnikova
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2018
Materias:	interleukin 33 fibrosis growth-stimulating factor Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/eb7ed017fcd2405ba0be2e762d2e8b27
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:eb7ed017fcd2405ba0be2e762d2e8b27
record_format	dspace
spelling	oai:doaj.org-article:eb7ed017fcd2405ba0be2e762d2e8b272021-11-18T08:03:47ZINTERLEUKIN 33 AND FIBROSIS: PATHOGENESIS UPDATED1563-06252313-741X10.15789/1563-0625-2018-4-477-484https://doaj.org/article/eb7ed017fcd2405ba0be2e762d2e8b272018-06-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/1557https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XInterleukin 33 (IL-33) is a member of the IL-1 family, which is widely expressed on all types of cells. IL-33 was identified as a functional ligand for the plasma membrane receptor complex, which is a heterodimer consisting of a membrane bound ST2 receptor (growth stimulating factor). IL-33 is involved in the development of immune response with predominant release of pro-inflammatory T helper type 2 cytokines. IL-33 is widely expressed on various structure-forming cells, such as epithelial, endothelial and smooth muscle cells. Increased expression of IL-33 is observed during necrosis of these cells (after tissue or cell damage), and it is released into extracellular space, and acts as an endogenous danger signal, sending a sort of warnings to neighboring cells and tissues. Recently, many studies have shown that IL-33 can participate in development and progression of fibrosis in various organs. However, it exerts anti-inflammatory effects upon development of other diseases. This review will discuss biological characteristics of IL-33 and a role of the IL-33/ST2 signaling pathway in the development of fibrosis.E. G. UchasovaO. V. GruzdevaYu. A. DilevaV. N. KaretnikovaSPb RAACIarticleinterleukin 33fibrosisgrowth-stimulating factorImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 20, Iss 4, Pp 477-484 (2018)
institution	DOAJ
collection	DOAJ
language	RU
topic	interleukin 33 fibrosis growth-stimulating factor Immunologic diseases. Allergy RC581-607
spellingShingle	interleukin 33 fibrosis growth-stimulating factor Immunologic diseases. Allergy RC581-607 E. G. Uchasova O. V. Gruzdeva Yu. A. Dileva V. N. Karetnikova INTERLEUKIN 33 AND FIBROSIS: PATHOGENESIS UPDATED
description	Interleukin 33 (IL-33) is a member of the IL-1 family, which is widely expressed on all types of cells. IL-33 was identified as a functional ligand for the plasma membrane receptor complex, which is a heterodimer consisting of a membrane bound ST2 receptor (growth stimulating factor). IL-33 is involved in the development of immune response with predominant release of pro-inflammatory T helper type 2 cytokines. IL-33 is widely expressed on various structure-forming cells, such as epithelial, endothelial and smooth muscle cells. Increased expression of IL-33 is observed during necrosis of these cells (after tissue or cell damage), and it is released into extracellular space, and acts as an endogenous danger signal, sending a sort of warnings to neighboring cells and tissues. Recently, many studies have shown that IL-33 can participate in development and progression of fibrosis in various organs. However, it exerts anti-inflammatory effects upon development of other diseases. This review will discuss biological characteristics of IL-33 and a role of the IL-33/ST2 signaling pathway in the development of fibrosis.
format	article
author	E. G. Uchasova O. V. Gruzdeva Yu. A. Dileva V. N. Karetnikova
author_facet	E. G. Uchasova O. V. Gruzdeva Yu. A. Dileva V. N. Karetnikova
author_sort	E. G. Uchasova
title	INTERLEUKIN 33 AND FIBROSIS: PATHOGENESIS UPDATED
title_short	INTERLEUKIN 33 AND FIBROSIS: PATHOGENESIS UPDATED
title_full	INTERLEUKIN 33 AND FIBROSIS: PATHOGENESIS UPDATED
title_fullStr	INTERLEUKIN 33 AND FIBROSIS: PATHOGENESIS UPDATED
title_full_unstemmed	INTERLEUKIN 33 AND FIBROSIS: PATHOGENESIS UPDATED
title_sort	interleukin 33 and fibrosis: pathogenesis updated
publisher	SPb RAACI
publishDate	2018
url	https://doaj.org/article/eb7ed017fcd2405ba0be2e762d2e8b27
work_keys_str_mv	AT eguchasova interleukin33andfibrosispathogenesisupdated AT ovgruzdeva interleukin33andfibrosispathogenesisupdated AT yuadileva interleukin33andfibrosispathogenesisupdated AT vnkaretnikova interleukin33andfibrosispathogenesisupdated
_version_	1718422388771651584

INTERLEUKIN 33 AND FIBROSIS: PATHOGENESIS UPDATED

Ejemplares similares